WELKOM,   Inloggen   |   Registreren Beursnieuws via RSS
Grafiek Oxurion (ex ThromboGenics)Oxurion (ex ThromboGenics)

BRU: OXUR | BE0003846632
Euronext Brussel
2,560 EUR   (-2,29%)
26 februari 2021

Kosten order 3.000 EUR: 2,90 EUR
Beleg goedkoper met DEGIRO Begin direct met beleggen bij DEGIRO* »
* Met beleggen kunt u uw inleg verliezen

Vandaag

2,580

2,650

12 maanden

2,140

3,310

Beleg goedkoper met DEGIRO
Kosten order 3.000 EUR: 2,90 EUR
Samenvatting Analisten Nieuws Agenda Insiders Grafiek Koersen

Laatste nieuws over Oxurion

Nieuws via RSS voor Oxurion (ex ThromboGenics)

Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer

20 januari 2021 - 08:00  |  Oxurion NV
Leuven, BE and Boston, MA, US - January 20, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on diabetic macular edema (DME), is pleased to announce the...
Trivano.com »

OXURION to Participate in Upcoming Investor Meetings

07 januari 2021 - 08:00  |  Oxurion NV
OXURION to Participate in Upcoming Investor Meetings Leuven, BELGIUM, Boston, MA, US - January 7, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on...
Trivano.com »

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

09 november 2020 - 07:30  |  Oxurion NV
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices Composition-of-matter patents protect THR-687 until 2039-2044 Leuven, Belgium and Boston, MA, November 9, 2020 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a...
Trivano.com »

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

22 oktober 2020 - 18:47  |  Oxurion NV
Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address.Preclinical Proof of Concept for Company’s priority...
Trivano.com »

Oxurion NV Business Update – Q3 2020

15 oktober 2020 - 08:00  |  Oxurion NV
Oxurion NV Business Update – Q3 2020 Progressing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – Beyond anti-VEGF First Patient dosed in Phase 2 study (‘KALAHARI’) evaluating THR-149, a potent plasma kallikrein inhibitor, for the...
Trivano.com »

Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer

13 oktober 2020 - 17:45  |  Oxurion NV

Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET

08 oktober 2020 - 08:00  |  Oxurion NV

Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET

08 oktober 2020 - 08:00  |  Oxurion NV

Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020

05 oktober 2020 - 10:00  |  Oxurion NV

Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020

05 oktober 2020 - 10:00  |  Oxurion NV

Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4

29 september 2020 - 08:00  |  Oxurion NV

Oxurion NV Business Update - H1 2020

17 september 2020 - 17:45  |  Oxurion NV

Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference

14 september 2020 - 08:00  |  Oxurion NV

Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference

14 september 2020 - 08:00  |  Oxurion NV

Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

11 september 2020 - 08:15  |  Oxurion NV

Oudere nieuwsberichten »
160x600